Portola Pharmaceuticals Inc. buy klostergang
Summary
This prediction ended on 19.04.20 with a price of €5.77. The BUY prediction by klostergang for Portola Pharmaceuticals Inc. performed very badly with a performance of -88.43%. klostergang has 50% into this predictionPerformance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Portola Pharmaceuticals Inc. | 0.012% | 0.012% | -32.057% | -67.867% |
iShares Core DAX® | -0.598% | 0.645% | 10.813% | 15.396% |
iShares Nasdaq 100 | -3.290% | -4.193% | 23.772% | 40.773% |
iShares Nikkei 225® | -0.796% | -0.582% | 8.390% | 8.288% |
iShares S&P 500 | -1.164% | -0.857% | 23.003% | 41.152% |
Comments by klostergang for this prediction
In the thread Portola Pharmaceuticals Inc. diskutieren
PORTOLA a potential takeover candidate
klostergang stimmt am 27.06.2017 der Outperform-Einschätzung der institutionellen Analysten mit dem Kursziel 70$ zu.
The shares surged again last week as the FDA granted approval to its compound BEVYXXA (betrixaban) which is an extended-duration anticoagulant, for the prevention of venous thromboembolism {VTE} in
hospitalized at-risk adult patients. Another huge potential catalyst is coming up in mid-August, this is when the FDA should approve Portfola’s second drug candidate ‘Andexx'.
I could see Portola becoming a logical buyout target by a larger player with an established sales force. This may be one reason that Oppenheimer, Morgan Stanly, Cowen & Co. and Citigroup all reissued Buy ratings yesterday with price targets proffered between $66 and $78 a share.
Cowen raised their price target from $45 to $70 and Citigroup went from $51 to $78 while mentioning Portola as a potential takeover candidate.
In the thread Trading Portola Pharmaceuticals Inc.
Stopped prediction by klostergang for Portola Pharmaceuticals Inc.
Portola Pharmaceuticals Inc.
03.06.15
07.12.15
07.12.15